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ABSTRACT 
Objectives: In this study, we aimed to evaluate the effect of systemic lymphadenectomy on 
overall and progression free survival in advanced stage of ovarian cancer. 
Material and methods: The data of ovarian cancer patients who had been admitted to our 
clinic between March 2008 and December 2019 were collected retrospectively. The patients 
who had received neo-adjuvant chemotherapy (NACT), those having undergone interval 
surgery, those who had non-epithelial ovarian cancer, those with residual tumour larger than 1 
cm and those with stage I-IIA were excluded from the study. 
Results: A total of 241 patients with inclusion criteria were included in the study. While 169 
patients (70.1%) had undergone systemic lymphadenectomy (SLND), 72 (29.9%) had not. 
Lymph node involvement was present in 105 out of 169 patients (62.1%) who had undergone 
SLND. There was no statistically significant difference between the groups in terms of SLND 
and lymph node involvement for both progression free survival (PFS) and overall survival 
(OS) (p = 0.577, p = 0.493, p = 0.481, p = 0.849 respectively). When subgroup analysis was 
performed according to the residual tumor amount, we could not find any statistically 
significant difference in both PFS and OS in terms of SLND and lymph node involvement in 
R0 (complete resection) group (p = 0.057, p = 0.917, p = 0.106 and p = 0.980 respectively). 
We found similar results for patients in the R1 (optimal resection) group. 
 
 
Conclusions: It was found that performing systemic lymphadenectomy had no effect on both 
progressive and overal survival. It should be kept in mind that the increasing number of 
malignant lymph nodes removed could have a therapeutic effect in OS. Large numbers of 
randomized clinical trials are required to enlighten this debatable issue that has been 
continuing, particularly in the recent two decades. 
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INTRODUCTION 
Approximately 1.3% of women will develop ovarian cancer during their lifetime and 
most of them will be in advanced stage at the time of diagnosis [1]. According to the 
GLOBOCAN 2018 data, 295.414 new ovarian cancer cases (1.6%) and 184.799 ovarian 
cancer-related deaths were reported among all cancers. It is the 8th leading cause of female 
cancers with an incidence of 3.4% and a mortality rate of 4.4% [2]. As target therapy, 
Bavesizumab (anti-vascular endothelial growth factor antibody) has been recommended in 
combination with chemotherapy (CT) or as maintenance therapy [3, 4]. Despite these 
treatment modalities, ovarian cancer remains the female genital cancer with the highest 
mortality rate [5]. The main treatment of ovarian cancer is reducing the tumour load either 
completely (complete = R0) or to below 1 cm (optimal = R1) and administration of six cycles 
of adjuvant carboplatin + paclitaxel chemotherapy as the post-surgery tumour amount is the 
most important prognostic factor [6, 7]. Lymphatic metastasis is also very common beside 
peritoneal spread. Therefore, lymphatic involvement has been accepted as a poor prognostic 
factor, in both early and advanced stage disease [8]. The lymphatic involvement rate has been 
reported as 60–72% in the literature [9]. Radical lymphadenectomy leads to severe morbidity 
[10, 13]. While some retrospective studies report that lymphadenectomy contributes to 
progression-free survival (PFS) and overall survival (OS) [6, 11], another randomized study 
has reported that it does not contribute to OS [12]. Although included in FIGO (The 
International Federation of Gynaecology and Obstetrics), lymphadenectomy was not shown to 
have a contribution to OS in advanced stage epithelial ovarian cancer patients who had 
undergone complete resection in a recent randomized controlled LION study [13].  
In the present study, it was aimed to present the results of our patients who had been 
diagnosed and who had undergone lymphadenectomy in the last 14 years under the light of 
the literature, which presents conflicting results about lymphadenectomy that is an important 




MATERIAL AND METHODS 
The data of ovarian cancer patients who had been admitted to our clinic between 
March 2008 and December 2019 were collected retrospectively. The study was evaluated by 
the Akdeniz University Faculty of Medicine Clinical Research Ethics Committee and was 
approved under the decision number KAEK-436. A routinely informed consent was taken 
from all participants. The patients who had received neo-adjuvant chemotherapy (NACT), 
those who had undergone interval surgery, those who had non-epithelial ovarian cancer, those 
with residual tumour larger than 1 cm and those with stage 1–2A were excluded from the 
study. The study's inclusion criteria were patients with epithelial ovarian cancer, stage 2b–4 
(including resectable stage 4b), who had undergone primary debulking surgery and had no 
second primary tumour. A total of 241 patients who fulfilled the inclusion criteria were 
included. All patients were classified according to the FIGO surgical staging system and 
operated by an expert surgeon in the gynaecological oncology field. All patients were 
compared in terms of age, tumor grade, histology, recurrence, lymph node involvement, 
number and location of malignant lymph nodes, number of malignant lymph nodes, residual 
tumour amount, death and follow-up time. The abdomen was accessed through an infra-
umbilical median incision and total abdominal hysterectomy and bilateral salpingo-
oophorectomy were carried out, an abdominal cytology specimen was obtained, total 
omentectomy±systemic lymphadenectomy (SLND) was carried out, small intestine and/or 
colon resection and splenectomy were performed, and the required surgical procedures were 
carried out depending on tumoral involvement. 
While systemic pelvic LND included the lymph nodes and the neighbouring fat tissues 
up to the mesial part of the common iliac artery beginning from the circumflex iliac vein 
including the lymph nodes in the obturator space, the para-aortic LND included the lymph 
nodes and the neighbouring fat tissues around the vena cava inferior in the cephalic direction 
from the mesial part of the common iliac artery and anterior side of the aorta, inferior and 
superior parts of the inferior mesenteric artery and at the level of the left renal vein. All the 
patients included in our study received six cycles of the standard adjuvant systemic 
chemotherapy at the time. The patients received carboplatin + paclitaxel chemotherapy as 
adjuvant therapy post-operatively and followed-up once every three months during the first 
two years, and once every six months during the following three years for recurrence. After 
completing the five-year follow-up, the gynaecological oncology and medical oncology 
clinics follow all patients for the rest of their lives. The patients were divided into two groups 
as those who had undergone systemic lymphadenectomy and those who had not. The patients 
 
 
were divided into three groups according to the number of removed lymph nodes, while 1–20 
lymph nodes were removed in the patients in Group 1, 21–40 LN were removed in Group 2 
and more than LNs were removed 41 in Group 3. 
 
Statistical analysis 
Descriptive statistics were expressed as mean, standard deviation, median, min-max 
values and frequencies. The statistical significance between the categorical variables was 
tested with the Chi-square test. The parametric and non-parametric tests were used for the 
numerical data depending on the normality distribution. The influence of clinical and 
pathological factors on overall survival was tested with the Kaplan-Meier log rank test. The 
effect of various prognostic factors on the survey alone or together was examined using the 
uni-variate or the multi-variate cox proportional hazards model. Statistical analyses were 
carried out using the SPSS ver. 23. P values in all tests were two-tailed and a p value of < 
0.05 was accepted as statistically significant. 
 
RESULTS 
The median age of the patients who had undergone SLND was 51.5 years (range 37–
85); the median was 54 (range 30–79) for patients who had not undergone SLND (p: 0.001). 
The median PFS was 16.0 months and the median OS was 65.3 months. While 169 patients 
(70.1%) had undergone SLND, 72 (29.9%) had not. The clinical and pathological 
characteristics of the patients have been presented in Table 1. 
The largest number of patients was in Stage 3 (85%) and there was a statistically 
significant relationship between the tumour stage and SLND (p: 0.003). A total of 161 
(66.8%) patients had serous histology followed by endometrioid type (13.6%). Of the 
patients, 220 had Grade 2–3 tumour. Fifty-five (22.8%) out of 62 (25.7%) patients who had 
undergone complete resection (R0) had undergone SLND. While 114 (47.2%) out of 179 
(74.2%) patients who had undergone optimal (R1) resection had undergone SLND, 64 
(26.9%) had not. Lymph node involvement was present in 105 out of 169 patients (62.1%) 
who had undergone SLND, and the median number of metastatic LN was 4 (min: 1–max: 62). 
Pelvic + para-aortic LN involvement was detected in 61 patients. While the median number of 
removed LNs was 46 (min: 9–max: 95), 41 or more LNs were removed in 107 (63.3%) 
patients. A weak and significant correlation was determined between the number of LNs and 
positive LNs (r: 0.344, r2 = 0.118 and p < 0.001). The median duration of follow-up was 57 
(range: 0.53–121) months. While 188 (78%) patients passed away, 53 (22%) survived. 
 
 
Recurrence developed in 198 (82.2%) patients and no recurrence developed in 43 (17.8%) 
(Tab. 1). There was no statistically significant difference between the two groups in terms of 
recurrence and death (p: 0.672 and p: 0.462, respectively). Both PFS (p < 0.001) and OS (p < 
0.001) were observed to impair as the tumour stage increased (Tab. 2). When the grade and 
histology were evaluated, there was no difference between the groups with regard to survival 
(p > 0.05). While the median PFS was 18 months in the SLND group, it was 13.1 months in 
patients who had not undergone SLND (p = 0.577). While the median PFS was 18.0 months 
in 105 patients who had LN involvement, it was 18.7 months in patients who did not have LN 
involvement (p = 0.493). However, no difference was found in OS in patients who had 
undergone SLND and who had LN involvement (p = 0.481, p = 0.849, respectively). Survival 
has been presented in Figure 1. It was observed that the number of removed LNs had no effect 
on PFS and OS (p = 0.092, p = 0.242, respectively). 
It was found that lymph node metastasis location had no effect on both PFS and OS (p: 
0.267 and p: 0.751 respectively). The patients were allocated to three groups according to the 
number of malignant LNs (Group 1: 1–5, Group 2: 6–10, Group 3: > 10). Statistically 
significant relationship was determined in OS as the number of malignant LNs increased (p = 
0.018). However, this effect was not observed in PFS. When the effect of the amount of 
residual tumour was analysed, the median PFS was 25.2 months in patients who had 
undergone R0, 13.9 months in patients who had undergone R1 (p < 0.001). The overall 
survival was seen to decrease as the amount of residual tumour increased (p < 0.001). In the 
uni-variate analysis, while there was a significant difference regarding stage and residual 
tumour (p < 0.05), there was also a difference in only stage in the multi-variate analysis (p < 
0.05). No difference was determined in SLND and LN involvement in either of the two 
analyses (p > 0.05) (Tab. 3). When subgroup analysis was performed according to the residual 
tumour amount, the median PFS was 21 months in SLND patients in the R0 group, 32 months 
in those who did not (p: 0.057), and 25 months in patients with LN involvement and 21 
months in patients without LN involvement (p: 0.917). In terms of OS, it was found that both 
SLND and LN involvement were not statistically different in the R0 group (p: 0.106 and p: 
0.980, respectively). When we looked at the R1 group, it was seen that both PFS and OS 
times of SLND and LN involvement were close to each other and there was no statistically 
significant difference (p: 0.530, p: 0.711, p: 0.471 and p: 0.464, respectively). Survival 





Pelvic and para-aortic lymphadenectomy is a common procedure in ovarian cancer. 
However, the effect of lymphadenectomy on overall survival has been a subject of debate in 
different studies. The constant effect of non-pelvic macroscopic tumour on survival has 
gradually secured its position and stage 3C retro-peritoneal lymph node involvement in FIGO 
1988 has been changed in FIGO 2014 and re-defined as stage 3A1. FIGO recommends 
lymphadenectomy due to the likelihood of up-stage in early-stage ovarian cancer [14]. 
According to the current NCCN guidelines, bulky nodes or suspected lymph nodes should be 
removed if possible or SLND should be performed in patients who have tumoral nodes of ≥ 2 
cm [15]. Although post-surgery treatment modalities are more standard in ovarian cancer, 
surgical treatment may vary depending on the spread of the disease and the preference of the 
surgeon. This is also valid for lymphadenectomy, because surgeons may not wish to add this 
procedure to the cyto-reductive procedure as challenging complications are more common in 
patients undergoing lymphadenectomy [10–13]. 
Lymphadenectomy has been emphasized to be an important prognostic risk factor in 
previous publications [6, 12]. Today, it is known that ovarian cancer may progress to 
lymphatic besides peritoneal spread, and that the presence of lymphatic involvement is 
associated with a poor prognosis [16]. It has been reported that occult metastases could be 
overlooked when SLND is not performed, and this could lead to early recurrences due to 
chemo-resistant disease [17]. Hence, many papers have been published about ovarian cancer 
and lymphadenectomy, a debatable issue, during the recent two decades. The likelihood of 
detection of metastatic lymph node is around 60% in the literature when lymphadenectomy is 
performed in advanced stage ovarian cancer [18, 19]. In our study, the number of patients 
who had undergone SLND and detected to have metastasis was 105 (62.1%), consistent with 
the literature. It should be investigated whether the number of removed lymph nodes has a 
contribution to survival or not. In a retrospective study of Eoh et al., less than 20 lymph nodes 
were removed in some ovarian cancer patients who had undergone optimal debulking and 
more than 20 lymph nodes in some others. While removal of more than 20 lymph nodes had a 
limited contribution to PFS (p = 0.059), it had a great contribution to OS (p = 0.001) [19]. In 
the Surveillance, Epidemiology and End Results (SEER) database of Zhou et al. [18], while 
lymphadenectomy was found to be useful in patients in whom < 10 lymph nodes had been 
removed and complete resection had been performed (p = 0.017), it was shown that it did not 
contribute to survival in those who had residues of < 1 cm and > 1 cm (p = 0.193, p = 0.656, 
respectively). In our study, no significant contribution was determined in OS despite having 
removed a sufficient number of lymph nodes (median = 46, range 9–95). When analysed 
 
 
according to the number of metastatic lymph nodes, it was found not to have a significant 
contribution to PFS; however, it had a statistically significant contribution to OS (p = 0.018). 
Determining an improvement in survival as the number of removed lymph nodes increases 
may be expected due to the reduced retro-peritoneal tumoral load. When analyzed according 
to metastatic lymph node location, we can clearly see that location has no effect on survival. 
Anyway, pelvic or paraaortic lymph involvement in FIGO staging does not increase the stage. 
When looking at this situation, it is understood that the main thing is the removal of malignant 
lymph nodes and/or bulky nodes. 
Although SLND is a prognostic risk factor, its contribution to survival is not clear. In a 
meta-analysis including three randomized controlled and 11 retrospective studies, while there 
was a difference in PFS in randomized studies, this difference was not observed in 
retrospective studies. It was found to have a positive effect on OS, both in early stage and 
advanced stage ovarian cancer. Furthermore, performing LND was associated with low 
recurrence rates [20]. In the study of Dubois et al. reviewing three randomized controlled 
studies, performing SLND was shown to significantly contribute to PFS and OS in advanced 
stage ovarian cancer patients who had undergone complete (R0) debulking [6]. In another 
meta-analysis, the presence of a significant positive effect in PFS and OS in advanced stage 
ovarian cancer patients who had undergone SLND was associated with the heterogeneity of 
the studies [21]. After the LION study, this issue continues to be discussed in the literature. In 
the last published meta-analysis, it was emphasized that systemic lymphadenectomy 
contributes significantly to the survival of patients who undergo optimal debulking in 
advanced stage ovarian cancer, but it does not have an advantage in patients who undergo 
complete resection. In addition, according to the results of only RCTs in this meta-analysis, it 
was stated that SLND had no effect on survival [22]. 
Despite the presence of studies indicating that lymphadenectomy has a contribution to 
survival, some others report no contribution [23]. In the most recent multi-centre randomized 
controlled study conducted to solve the debate on this issue (LION study), while SLND was 
performed in 323 out of 647 advanced stage (Stage 2b–4) ovarian cancer patients who had 
normal lymph nodes before and during surgery and who had undergone complete resection, it 
was not performed in 324. The median number of removed lymph nodes was 57 and the rate 
of lymph node metastasis was 55.7%. The median PFS was 25.5 months for both groups (p = 
0.29). While the median OS was 65.5 in the SLND group, it was 69.2 in the other group (p = 
0.65). While the rate of complications was 2.4% with no contribution, it was 6.5% in the other 
group (p = 0.01), and the 60-day mortality rate was 3.1% vs 0.9% (p = 0.049) [13]. In our 
 
 
study, while the median PFS was 18 months in patients who had undergone SLND, it was 
13.1 months in patients who had not (p = 0.577). A similar neutral effect was found in 
patients who had undergone lymphadenectomy and those who did not have lymph node 
involvement (p = 0.493). This situation shows us that peritoneal spread is at the forefront and 
more effective on recurrence than lymphatic spread. 
While the median OS was 71.1 months in the SLND group in our study, it was 58 
months in the group that had not undergone SLND (p = 0.481). No significant difference was 
determined in OS in the group with lymph node metastasis (p = 0.849). In a recent meta-
analysis, 2 of the 7 studies that were randomized clinical trials investigated lymphadenectomy 
in advanced stage ovarian cancer. While lymphadenectomy led to a significant improvement 
in OS [hazard ratio (HR) = 0.64; 95% confidence interval (CI): 0.49–0.84, p < 0.01], this 
effect was not seen in PFS (HR = 0.89, 95% CI: 0.69–1.15, p = 0.38). In the subgroup 
analysis, it was reported that it did not affect the PFS (HR = 1.09, 95% CI: 0.91–1.30, p = 
0.33) and OS (HR = 0.81, 95% CI: 0.66–1.00, p = 0.05) [24]. In the uni-variate analysis in our 
study, although the mortality risk decreased in patients who had undergone SLND, there was 
no statistically significant difference (HR = 0.89; 95% CI: 0.65–1.22, p = 0.480). 
In addition, in another recent meta-analysis in which 4 RCTs were included, it was 
emphasized that systemic lymphadenectomy did not contribute to both PFS and OS in 
advance stage ovarian cancer. In addition, it was shown that severe complications were more 
common in patients who underwent SLND [25] So even methanalysis still offers 
controversial results on this matter. 
The effect of systemic lymphadenectomy on survival is still unclear according to the 
amount of residual tumor. There are studies showing that SLND has a significant effect on 
survival in patients with complete resection, but SLND does not have an effect on patients 
with optimal and sub-optimal debulking [17, 22]. When the opinion that SLND should be 
added to surgery if complete (R0) debulking is to be performed, a prospective randomized 
LION study was designed to reveal the effect of lymphadenectomy in patients with R0 [12]. 
According to the results of our own study, SLND and lymph node involvement in both R0 
(complete) and R1 (optimal) debulking patients did not statistically contribute to short and 
long term survival. We see that these results are similar to the results of the most recently 
published LION study. 
The present study has some limitations. Bias could be present in the patient selection 
due to the retrospective design of the study. However, the clinical and prognostic risk factors 
were attempted to be equal in both groups. Standardization of medical therapies was not 
 
 
known, particularly with regard to target therapy. The study could have included some 
prognostic risk factors such as the amount of ascites at the time of first admission, the 
platinum status and the post-operative complications. 
 
CONCLUSIONS 
In conclusion, it was found that performing systemic lymphadenectomy had no effect 
on both progressive and overal survival. It should be kept in mind that the increasing number 
of malignant lymph nodes removed could have a therapeutic effect in OS. Large numbers of 
randomized clinical trials are required to enlighten this debatable issue that has been 
continuing, particularly in the recent two decades. 
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Figure 1. A. Lympadenectomy status and progression free survival; B. Lymp node 
involvement and progression free survival; C. Lympadenectomy status and overall survival; 
D. Lymp node involvement and overall survival 
 
Table 1. Clinical and pathological characteristics of the patients 















































































































































































Table 2. The effect of clinical and surgical parameters on overall survival and progression-free 
survival 
   PFS     OS    
   mo CI %95 p  mo CI %95 p 












































































































































PFS — progression free survival; OS — overall survival; CI — confidence interval 
 
Table 3. Cox regression hazard model for overall survival 
Uni-variate analysis    Multi-variate 
analysis 























































































































































  HR 95% 
CI 
  P  HR 95% 
CI 
  P 
   lower upper     lower upper   
Age   1.01 0.99 1.02  0.120       
Grade   0.98 0.59 1.65  0.960       
Stage (2b ≤)  4.0 2.03 7.88  0.001  3.48 1.64 7.35  0.001 
Lymphadenectomy  0.89 0.65 1.22  0.480       
LN involvement  1.03 0.55 1.54  0.850       
Residual tumour  1.78 1.24 2.56  0.002  1.19 0.80 1.76  0.382 
HR — hazard ratio; CI — confidence interval 
 
Table 4. Progression-free and overall survival analysis of lymphadenectomy and lymph node 
involvement in patients with complete (R0) and optimal (R1) cytoreduction 
  PFS    OS  











SLND (+) 21 (12–29) 0,057   78 (66–89) 0.106 









21 (13–28)    73 (49–96)  
        





SLND (+) 15 (11–20) 0,530   65 (54–75) 0.471 




15 (9–20) 0,711   74 (63–84) 0.464 
 
 
 Lymph node 
involvement 
(–) 
17 (13–22)    57 (42–74)  
        
        
        
 
SLND — systemic lymphadenectomy; PFS — progression free survival; OS — overall 
survival; CI — confidence interval 
 
 
 
